Search results :

Cancidas

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: J02AX04

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10
Infection 30% - 54% x
Infestation NOS 30% - 54% x
Gastrointestinal disorder postmarketing, 30% - 55% x x x
Mediastinal disorder 23% - 54% x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing, 15% - 42% x x
Malnutrition 1.9% - 24% x x x
Blood alkaline phosphatase increased 13% - 32% x
Angiopathy 15% - 38% x x x
Body temperature increased 1.1% - 69.7% x x x x x x x x
Cardiac disorder 13% - 34% x x x
Nervous system disorder 0% - 27% x x x
Aspergillosis 13% x
Blood and lymphatic system disorders 2% - 15% x x
Blood potassium decreased 3.5% - 32% x x x
Aspartate aminotransferase increased 1.9% - 22.7% x x x x x x x x
Haemoglobin decreased common, 0.9% - 37.1% x x x x x x x x x x
Connective tissue disorder 11% - 14% x x
Septic shock 9% - 14% x
Pleural effusion 9% - 14% x
Blood bilirubin increased 0.6% - 17% x x
Phlebitis 3.5% - 22.5% x x x x x x x x x x
Thrombophlebitis 3.5% - 22.5% x x x x x x x x x
Oedema peripheral postmarketing, 11% - 12% x x x x x x x x x
Blood creatinine increased 3% - 28% x x
Respiratory failure 2% - 20% x
Alanine aminotransferase increased 2% - 22.7% x x x x x x x x
Phosphatase alkaline increased 2% - 19.3% x x x x x x x x
Blood urine 10% x x
Cough 6% - 11% x x
Pneumonia 4% - 11% x
Bilirubin conjugated increased 5% - 14% x
Blood magnesium decreased 7% - 9% x x
White blood cell count decreased common, 4.6% - 19% x x x x x x x x x x
Headache 0% - 19.1% x x x x x x x x x x
Rales 7% - 8% x x
Blood albumin decreased 7% - 8% x x
Blood glucose increased 6% - 9% x x
Haematocrit decreased common, 0.9% - 32.6% x x x x x x x x x
Abdominal pain 1.4% - 12% x x x x x x
Immune system disorder 7% - 12% x
Serum albumin decreased 4.6% - 14.9% x x x x x x x
Sepsis 5% - 7% x
Mucosal inflammation 4% - 10% x
Nausea 0% - 21.3% x x x x x x x x x x
Chills 0% - 75.3% x x x x x x x x x x
Hypertension 1.1% - 10% x x x x x x x x
Serum potassium decreased 2.9% - 31.5% x x x x x x x
Hypokalaemia 0% - 11.8% x x x x x x x x
Decubitus ulcer 3% - 5% x
Graft versus host disease 1% - 8% x
Respiratory distress 0% - 8% x
Dyspnoea 0% - 10% x x x x x x x x
Urinary protein increased 0% - 4.9% x x x x x x x
Rash 0% - 23% x x x x x x x x x x
Vomiting 0.6% - 17% x x x x x x x x x x
Diarrhoea 0.8% - 27% x x x x x x x x x x
Eosinophilia 1.1% - 3.2% x x x x x x x x
Serum total protein decreased 0% - 3.4% x x x x x x x
Neutropenia 1.1% - 3.2% x x x x x x
Blood potassium increased 0% - 8% x x
Flushing 0% - 4.2% x x x x x x x x x x
Injection site phlebitis 2% - 3.8% x x
Back pain 0% - 8% x x x x x x
Sweating increased 2.2% - 2.8% x x x x
Serum bilirubin increased 0% - 8.9% x x x x x x x
Hypomagnesaemia 2.3% - 2.6% x x x x x x x
Hypotension 0.9% - 20% x x x x x x x x x
Platelet count decreased uncommon, 1.5% - 3.4% x x x x x x x x
Serum creatinine increased 0% - 28.1% x x x x x x x
Tachycardia 0% - 19% x x x x x x x x x x
Blood phosphorus decreased 0% - 2% x x
Hyponatraemia 0% - 3.8% x x x x x x x x
Injection site swelling 1% - 2% x x
Serum calcium decreased 0% - 3.2% x x x x x x x
Prothrombin level increased 0% - 2.3% x x x x x x x x
Pain 0% - 9% x x x x x x x x
Erythema 0% - 9% x x x x x x x x x x
Pruritus 0% - 8% x x x x x x x x x x
Blood urea increased 0% - 23% x x x x x x x x x
Myalgia 0% - 3.1% x x x x x x x x
Catheter site pain 0% - 3.6% x x x
Dizziness 0% - 2.13% x x x x x x x x x
Paraesthesia 0% - 3.1% x x x x x x x x
Injection site erythema 0% - 2% x x
Central line infection 0% - 9% x
Serum potassium increased 0% - 2.4% x x x x x x x
Jaundice 0% - 3.8% x x x x x x x x
Sweating 0% - 3.4% x x x x x x x x
Renal impairment 0% - 5.6% x x x x x x
Lymphocyte count increased 0% - 2.2% x x x x x x x
Coagulopathy uncommon x x
Thrombocytopenia uncommon x x
White blood cell count increased uncommon x
Thrombocytosis uncommon x
Neutrophil count decreased uncommon x
Lymphocyte count decreased uncommon x
Eosinophil count increased uncommon x
pH urine increased 0% - 3.6% x x x x x x x x
Uric acid increased 0% - 3.4% x x x x x x x
Erythema multiforme postmarketing x x
Pancreatitis postmarketing x
Urinary tract disorder postmarketing x x
Hepatic necrosis postmarketing x
Skin exfoliation postmarketing x
Hepatobiliary disease postmarketing x x x
Abdominal distension x x
Acquired immunodeficiency syndrome x
Anaphylactic shock 0% - 2.2% x x x x x x x x x
Anaemia uncommon, 0% - 11% x x x x x x x x x x
Angioedema 0% - 3.8% x
Anorexia 0% - 3.4% x x x x x x x x x
Anxiety x x
Arrhythmia x x
Arthralgia x x x
Ascites x
Asthenia 0% - 6.7% x x x x x x x x
Atrial fibrillation x x
Bacteraemia x
Mental disorder x x
Bone disorder x
Bronchospasm x x x x x x x
Neoplasm malignant x x x x x x x x x
Chest pain x
Cholestasis x
Confusional state x
Constipation x x
Dysphagia x
Dermatitis atopic x
Dysgeusia x
Dyspepsia x x
Oedema 0% - 8% x x x x x x x x x
Epistaxis x
Eye disorder x
Fatigue 0% - 6.7% x x x x x x x x x
Flatulence x
Gastritis 0% - 2.1% x x x x x x x
Cardiac arrest x
Cardiac failure congestive x
Haematuria 0% - 4% x x x x x x x x
Hepatitis 0% - 3.8% x
Hepatomegaly x x
Hyperbilirubinaemia 0% - 3.8% x x x x x x
Hypercalcaemia x x x x x x x x x
Hyperglycaemia x x
Hyperhidrosis x
Hypersensitivity x x x x
Hypoaesthesia x
Hypocalcaemia x
Renal failure acute x
Laryngospasm 0% - 3.8% x
Liver disorder x
Myocardial infarction x
Nasal congestion x
Neoplasm x x x
Opportunistic infection x
Pain in extremity x x
Palpitations x
Petechiae x
Prurigo x
Pulmonary oedema x x x x x x x x x
Renal failure x x
Acute respiratory distress syndrome x x x x
Convulsion x
Skin lesion x
Stridor x
Swelling postmarketing, 0% - 5.6% x x x x x x x x x x
Tremor 0% - 7.9% x x x x x x x x x
Urinary tract infection x
Urticaria x x
Vasculitis 0% - 3.4% x x x x x x x
Wheezing x
Dry mouth x
Hepatic failure x
Burning sensation x
Hepatic function abnormal x x x x x x x x
Swelling face x x x x x x
Gamma-glutamyltransferase increased x
Muscular weakness x
Bone pain x
Injection site pain x
Lacrimation increased x
Eyelid oedema x
Metabolic acidosis x
Rash macular x
Malaise 0% - 5.6% x x x x x x x x
Tachypnoea 0% - 11% x x x x x x x x x
Breath sounds abnormal x
Decreased appetite x
Abdominal pain upper x x
Disorientation x
Tenderness x
Rash erythematous x
Rash morbilliform x
Upset stomach x
Hepatotoxicity x x
Chest discomfort x
Circumoral oedema 0% - 3.8% x
Activated partial thromboplastin time prolonged x
Solid tumour x x x x x x x
Induration 0% - 6.7% x x x x x x x x
Electrolyte imbalance x
Vision blurred x
Haematological malignancy x x x x x x x
Rash maculo-papular x
Bradycardia x
Pruritus generalised x
Blood pressure increased x
Rash generalised x
Influenza like illness 0% - 3.1% x x x x x x x
Bicarbonate decreased serum 0% - 6.6% x x x x x x x
Face oedema x
Fluid overload x x
Feeling of body temperature change x
Sensation of warmth x x x x x x
Serum phosphate increased 0% - 2.7% x x x x x x
White blood cells urine positive x
Prothrombin time shortened x
Blood sodium increased x
Blood chloride increased x
Blood chloride decreased x
Nephrotoxicity x x x x x x x
Hot flush x
Direct bilirubin increased 0% - 6.3% x
Bilirubin total increased x
Febrile neutropenia x
Blood bicarbonate decreased x
International normalised ratio increased x
Local reaction x
Blood uric acid decreased x
Elevated liver enzyme levels x x x
Pharyngolaryngeal pain x
Carbon dioxide decreased x
Glucose increased x x
Albumin low x
Potassium low x x
Protein total decreased 0% - 8% x x
Infusion site erythema x
Insomnia 0% - 2.2% x x x x x x x x x
Blood phosphorus increased x
Phosphorus low x x
Blood urine present x
Immunosuppressant drug level increased x
Protein urine present x
Infusion site induration x
Infusion site pain x x
Infusion site swelling x
Infusion site pruritus x x
Infusion site phlebitis x
Ocular icterus x
Infusion site rash x
Infusion site extravasation x
Infusion site irritation x
Infusion site urticaria x
Dyspnoea paroxysmal nocturnal x
Somnolence x x
Feeling hot x
Blood calcium decreased x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

caspofungin acetate / Cancidas

Side effects:66
Source:FDA

CASPOFUNGIN ACETATE / CANCIDAS

Side effects:75
Source:FDA

caspofungin acetate / Cancidas

Side effects:75
Source:FDA

CASPOFUNGIN ACETATE / CANCIDAS

Side effects:81
Source:FDA

CASPOFUNGIN ACETATE / CANCIDAS

Side effects:81
Source:FDA

CASPOFUNGIN (CASPOFUNGIN ACETATE) / CANCIDAS

Side effects:84
Source:Health Canada

caspofungin acetate / CANCIDAS

Side effects:98
Source:medicines.org.au

CASPOFUNGIN

Side effects:125
Source:FDA Structured Product Label

caspofungin / caspofungin

Side effects:183
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label